Published in Lancet Oncol on October 10, 2016
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med (2017) 1.40
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol (2016) 0.81
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Front Oncol (2017) 0.79
Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov (2017) 0.78
Lung cancer: Anti-PD-1 therapy in the frontline. Nat Rev Clin Oncol (2016) 0.76
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res (2017) 0.76
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. Oncotarget (2017) 0.75
Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016. Ecancermedicalscience (2016) 0.75
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. Front Med (Lausanne) (2017) 0.75
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer. Clin Transl Med (2017) 0.75
Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer". Transl Lung Cancer Res (2016) 0.75
Emerging therapies for breast cancer. J Hematol Oncol (2017) 0.75
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Curr Oncol Rep (2017) 0.75
PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget (2017) 0.75
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. Front Oncol (2017) 0.75
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med (2017) 0.75
Pembrolizumab-Induced Pancytopenia: A Case Report. Perm J (2017) 0.75
Standard of care in immunotherapy trials: Challenges and considerations. Hum Vaccin Immunother (2017) 0.75
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer (2017) 0.75
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. Br J Cancer (2017) 0.75
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. Curr Oncol Rep (2017) 0.75
Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome. Clin Cancer Res (2017) 0.75
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. Gastrointest Cancer (2017) 0.75
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Transl Lung Cancer Res (2017) 0.75
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…. ESMO Open (2017) 0.75
ESMO Copenhagen 2016: a lung cancer 'grand cru'. ESMO Open (2017) 0.75
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. Lung Cancer (Auckl) (2017) 0.75
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol (2015) 2.60
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol (2016) 1.84
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol (2016) 0.90
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs (2017) 0.76
Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma (2004) 0.75